Inogen (NASDAQ:INGN) Share Price Passes Below Two Hundred Day Moving Average – Here’s Why

Shares of Inogen, Inc (NASDAQ:INGN) passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $7.33 and traded as low as $5.80. Inogen shares last traded at $5.84, with a volume of 172,700 shares.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Inogen in a research note on Monday, December 22nd. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $11.00.

Inogen Stock Down 1.8%

The business has a 50-day simple moving average of $6.58 and a two-hundred day simple moving average of $7.33. The stock has a market capitalization of $158.54 million, a price-to-earnings ratio of -5.78 and a beta of 1.79.

Inogen (NASDAQ:INGN) last posted its quarterly earnings data on Wednesday, November 5th. The medical technology company reported ($0.20) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.02. Inogen had a negative return on equity of 13.21% and a negative net margin of 7.31%.The company had revenue of $92.39 million for the quarter, compared to the consensus estimate of $92.20 million. On average, analysts forecast that Inogen, Inc will post -1.73 EPS for the current year.

Hedge Funds Weigh In On Inogen

Large investors have recently made changes to their positions in the business. Perkins Capital Management Inc. grew its stake in shares of Inogen by 7.3% in the 4th quarter. Perkins Capital Management Inc. now owns 217,650 shares of the medical technology company’s stock worth $1,463,000 after purchasing an additional 14,850 shares during the last quarter. Torren Management LLC bought a new position in shares of Inogen in the fourth quarter valued at $51,000. R Squared Ltd acquired a new stake in shares of Inogen during the 4th quarter valued at $193,000. Clark Asset Management LLC acquired a new stake in shares of Inogen during the 4th quarter valued at $144,000. Finally, Tudor Investment Corp ET AL boosted its stake in shares of Inogen by 5.7% during the 3rd quarter. Tudor Investment Corp ET AL now owns 137,650 shares of the medical technology company’s stock worth $1,125,000 after acquiring an additional 7,415 shares in the last quarter. Institutional investors own 89.94% of the company’s stock.

Inogen Company Profile

Inogen, Inc (NASDAQ: INGN) is a medical device company specializing in the development, manufacture and marketing of innovative oxygen therapy solutions. The company’s core focus is on portable oxygen concentrators (POCs) designed to support patients with chronic respiratory conditions such as chronic obstructive pulmonary disease (COPD). Inogen’s offerings aim to provide users with mobility and independence by reducing reliance on traditional compressed-gas cylinders and enabling oxygen therapy on the go.

Inogen’s flagship product line, including the Inogen One family of portable oxygen concentrators, leverages proprietary flow technology to deliver continuous and pulse-dose oxygen.